Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. [electronic resource]
Producer: 20101108Description: 4621-9 p. digitalISSN:- 1527-7755
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Boronic Acids -- administration & dosage
- Bortezomib
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Europe
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multiple Myeloma -- diagnosis
- Neoadjuvant Therapy
- Neoplasm Staging
- Protease Inhibitors -- administration & dosage
- Pyrazines -- administration & dosage
- Stem Cell Transplantation
- Time Factors
- Transplantation, Autologous
- Treatment Outcome
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.